DA
PLX icon

Denali Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Denali Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-94,700
Closed -$169K – 489
2023
Q4 		$169K Sell
94,700
-15,500
-14% -$24.1K 0.05% 239
2023
Q3 		$183K Hold
110,200
– – 0.06% 234
2023
Q2 		$220K Buy
+110,200
New +$263K 0.08% 208

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Denali Advisors's PLX Position: Q1 2024 in Review

Denali Advisors sold out of Protalix BioTherapeutics (PLX) in Q1 2024, closing a stake of 94,700 shares — an estimated $169K sold.

Denali Advisors first reported a position in PLX in Q2 2023 and held it in 3 quarters. The position peaked at $220K in Q2 2023. 63 funds tracked by Wall St. Rank hold PLX as of Q1 2024.

  • Denali Advisors reported no remaining Protalix BioTherapeutics position as of Q1 2024 after selling out during the quarter.
  • Denali Advisors sold 94,700 Protalix BioTherapeutics shares in Q1 2024, an estimated $169K.
  • Denali Advisors first reported a position in Protalix BioTherapeutics in Q2 2023 and held it in 3 quarters.
  • Denali Advisors's Protalix BioTherapeutics position peaked at $220K in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2024.

Based on Denali Advisors's 13F filing for Q1 2024, filed 19 Apr 2024.